A phase I dose escalation study of weekly BI 836845, a fully human, affinity-optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers.
Chia-Chi Lin
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Kwang-Yu Chang
No relevant relationships to disclose
Dennis C Huang
Employment or Leadership Position - Boehringer Ingelheim
Vicky Marriott
Employment or Leadership Position - Boehringer Ingelheim
Ludy Van Beijsterveldt
Employment or Leadership Position - Boehringer Ingelheim
Li-Tzong Chen
No relevant relationships to disclose
Ann-Lii Cheng
No relevant relationships to disclose